EDITAS MEDICINE INC (EDIT)
US28106W1036 - Common Stock
EDIT Stock Earnings: Editas Medicine Misses EPS, Misses Revenue for Q1 2024
EDIT stock results show that Editas Medicine missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024.
Editas Medicine Announces First Quarter 2024 Results and Business Updates
Editas Medicine Announces First Quarter 2024 Results Conference Call and Upcoming Investor Events
Editas Medicine Announces First Quarter 2024 Results Conference Call and Upcoming Investor Events
CAMBRIDGE, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage gene editing company, today announced that it...
Editas Medicine and Bristol Myers Squibb Extend Alpha-Beta T Cell Collaboration
Two-year extension for research and development of alpha-beta T cell medicines for the treatment of cancer and autoimmune diseases
Editas Medicine and Bristol Myers Squibb Extend Alpha-Beta T Cell Collaboration
Two-year extension for research and development of alpha-beta T cell medicines for the treatment of cancer and autoimmune diseases...
Editas Medicine to Present Pre-clinical Data Demonstrating Progression of in vivo Medicines Pipeline at the American Society of Gene and Cell Therapy Annual Meeting
CAMBRIDGE, Mass., April 22, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage gene editing company, today announced that...
First Week of EDIT May 3rd Options Trading
EDIT April 26th Options Begin Trading
1 Wall Street Analyst Raises Editas Medicine's Price Target by 45%. Here's Why She's Right.
The company now has a chance to get its lead program out the door a bit sooner.
1 Beaten-Down Stock With 55% Upside, According to Wall Street
The biotech has bounced back some in the past year.
Why Editas Medicine Stock Soared as Much as 42% Higher This Week
The clinical-stage genome editing company dropped a couple of important announcements for shareholders.
Editas Medicine files for mixed shelf offering (NASDAQ:EDIT)
Editas Medicine files a prospectus for a mixed shelf offering, without disclosing the amount.
Notable Wednesday Option Activity: MSFT, EDIT, CSTL
TG Therapeutics Soars On In-Line Report; Is The Biotech Rally Buoying Shares?
The company reported in-line sales for the fourth quarter, but shares soared by double digits.
Editas stock rises as Vertex deal drives Q4 beat (NASDAQ:EDIT)
Editas Medicine (EDIT) stock gains after reporting posting a strong Q4 beat in revenue thanks to a collaboration agreement with Vertex Pharma (VRTX). Read more here.
Editas Medicine GAAP EPS of -$0.23 beats by $0.23, revenue of $60.04M beats by $52.32M (NASDAQ:EDIT)
Editas Medicine reported better-than-expected Q4 results with a GAAP EPS beat of $0.23 and revenue of $60.04M, surpassing estimates significantly.
Editas Medicine Announces Fourth Quarter and Full Year 2023 Results and Business Updates
Editas Medicine Announces Fourth Quarter and Full Year 2023 Results and Business Updates
Company aligned with FDA that RUBY is a single Phase 1/2/3 trial
Editas Medicine Breaks Above 200-Day Moving Average - Bullish for EDIT
Editas Medicine Announces Fourth Quarter and Full Year 2023 Results Conference Call and Upcoming Investor Events
Editas Medicine Announces Fourth Quarter and Full Year 2023 Results Conference Call and Upcoming Investor Events
CAMBRIDGE, Mass., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced that...
Editas Medicine to Participate in Upcoming Investor Conferences
2 Under-the-Radar Stocks With Incredible Upside Potential
It's also important to consider their downsides.
Could Editas Medicine Become the Next CRISPR Therapeutics?
The similarities between the pair are striking, but it might not be enough.
Editas Medicine Enters Oversold Territory (EDIT)
Notable Two Hundred Day Moving Average Cross - EDIT
7 Mighty Healthcare Stocks Changing the Game of Medicine
Thanks to the permanent relevance of medical innovations, investors ought to consider looking at these healthcare stocks.
Down 88%, Could Editas Medicine Be a Good Investment Now?
The past few years have been difficult ones, but shares of the gene editor are far more attractive now that a CRISPR medicine has passed regulatory hurdles.
3 Stocks to Buy in the Booming Field of Gene Editing
As the promise of gene editing moves closer to being a reality, these gene editing stocks have the opportunity for long-term gains.
Editas Medicine Highlights 2024 Anticipated Milestones and Strategic Priorities at the J.P. Morgan Healthcare Conference
Editas Medicine Highlights 2024 Anticipated Milestones and Strategic Priorities at the J.P. Morgan Healthcare Conference
Anticipated 2024 milestones include: present reni-cel clinical data updates mid-year and year-end, initiate the RUBY clinical trial adolescent cohort,...
Better Gene-Editing Stock: Editas Medicine vs. Intellia Therapeutics
These two are at very different stages of the clinical trials process.